Clinical Trials on NK/T Cell Lymphoma Nos in Japan

Total 556 results

Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension

Metastatic Non-small Cell Lung Cancer

Japan
Eli Lilly and Company
Merck Sharp & Dohme LLC

Completed

A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC

Stage IV Non-Small Cell Lung Cancer

Spain, United States, France, Japan
Sumitomo Pharma Co., Ltd.

Completed

A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma

Non-Small Cell Lung Cancer | Malignant Pleural Mesothelioma

Japan
Eisai Co., Ltd.

Recruiting

A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan

Lymphoma, Follicular

Japan
Pfizer

Completed

Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients

ALK-positive Non-small-cell Lung Cancer

Japan
Boehringer Ingelheim

Completed

BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I

Carcinoma, Non-Small-Cell Lung

Japan
Celgene

Completed

Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) (AUGMENT)

Lymphoma, Non-Hodgkin

United States, Spain, China, Belgium, France, United Kingdom, Israel, Turkey, Russian Federation, Italy, Brazil, Czechia, Portugal, Germany, Japan, Poland, Puerto Rico
Pfizer
UCB Pharma

Completed

A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

United States, Canada, France, Spain, China, United Kingdom, Australia, Taiwan, Singapore, Korea, Republic of, Japan, Germany, Czechia, Poland, Italy, Netherlands, Argentina, Finland, Hungary, Sweden
Pfizer

Completed

A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)

Follicular Lymphoma

United States, Spain, United Kingdom, Korea, Republic of, France, Portugal, India, Mexico, Switzerland, Japan, Germany, Romania, Greece, Austria, Belgium, Italy, Thailand, Croatia, Philippines, Russian Federation, Puerto Rico, Ukr... and more
Helsinn Healthcare SA
ICON Clinical Research

Recruiting

Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities ((MARGARET))

RET-altered Solid Tumors | RET-altered Non Small Cell Lung Cancer

United States, Japan
Genmab
AbbVie

Recruiting

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1)

Follicular Lymphoma (FL)

Austria, Greece, Israel, Korea, Republic of, Spain, Hungary, Sweden, Switzerland, France, Poland, Taiwan, Australia, Denmark, New Zealand, Turkey, Italy, Netherlands, Belgium, Canada, South Africa, Czechia, Brazil, Germany, Argentina, United... and more
Princess Maxima Center for Pediatric Oncology
University of Milano Bicocca; Amgen Europe B.V

Recruiting

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia (Interfant-21)

Acute Lymphoblastic Leukemia | Mixed Phenotype Acute Leukemia

Norway, Finland, Denmark, Netherlands, Hungary, Argentina, Australia, Austria, Belgium, Czechia, France, Germany, Ireland, Italy, Japan, Portugal, Saudi Arabia, Sweden
Novartis Pharmaceuticals

Completed

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Advanced Non-small Cell Lung Cancer

Spain, Canada, Germany, Korea, Republic of, Taiwan, United States, Japan, Netherlands, Singapore
Hutchmed

Active, not recruiting

Open-label Study of Surufatinib in Japanese Patients

Neuroendocrine Tumors | Non-hematologic Malignancy

Japan
AbbVie

Recruiting

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (LIVIGNO-4)

Non-Small Cell Lung Cancer

United States, Israel, Japan
National Hospital Organization Nagoya Medical Center

Recruiting

ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016

Acute Lymphoblastic Leukemia | Down Syndrome | Childhood Cancer

Taiwan, Thailand, Hong Kong, Singapore, Malaysia, Japan
Kyowa Kirin, Inc.

Recruiting

A Study of KK2269 in Adult Participants With Solid Tumors

Gastric Adenocarcinoma | Non Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Japan
AbbVie

Recruiting

A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer (METRIX)

Non Small Cell Lung Cancer

Canada, United Kingdom, Argentina, Japan, Switzerland
Daiichi Sankyo

Recruiting

HER3-DXd in Metastatic or Unresectable Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Spain, Japan, Netherlands, Taiwan
Novartis Pharmaceuticals

Terminated

A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.

Melanoma | Ovarian Neoplasms | Non-Small-Cell Lung Carcinoma | Other Solid Tumors

Spain, Germany, Singapore, Switzerland, Japan, United States
Amgen

Recruiting

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

Japan, Australia, Denmark, Netherlands, Taiwan, Switzerland, Canada, France, United States, Austria, Italy, Spain, Sweden, Belgium, Hungary, Finland, Korea, Republic of, Greece, Turkey, Romania, Portugal, Germany, Bulgaria, Mexico, United...
Spectrum Pharmaceuticals, Inc

Terminated

Study of Poziotinib in Japanese Patients With NSCLC

NSCLC

Japan
Novartis Pharmaceuticals

Terminated

Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy (A+B)

Lymphoma, Follicular

United States, Belgium, Italy, Hong Kong, Austria, Germany, Japan, Russian Federation, United Kingdom, Canada, Slovakia, Poland, Ukraine, Puerto Rico, Greece, France, Argentina
Hoffmann-La Roche

Completed

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

Non-Squamous Non-Small Cell Lung Cancer

Spain, Taiwan, Japan, United States, France, Germany, Korea, Republic of, Malaysia
Pfizer

No longer available

Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC

Neoplasms | Carcinoma, Non-Small-Cell Lung

Japan
Takeda

Terminated

A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin

Spain, China, United States, France, United Kingdom, Germany, Canada, Italy, Japan
Novartis Pharmaceuticals

Terminated

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Colorectal Cancer | Gastrointestinal Stromal Tumors | Non-small Cell Lung Carcinoma | Head and Neck Squamous Cell Carcinoma | Esophageal SCC

United States, Germany, Spain, Singapore, Australia, Hong Kong, Belgium, Japan, China
Samsung Bioepis Co., Ltd.

Recruiting

A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage IV

Georgia, India, Romania, Spain, Germany, Japan, Malaysia
Boehringer Ingelheim

Terminated

BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Japan
Novartis Pharmaceuticals

Terminated

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy (GEOMETRY-E)

Carcinoma, Non-Small-Cell Lung

Japan, Korea, Republic of, Singapore
Bayer

Recruiting

A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors

Advanced Solid Tumors | Non-small Cell Lung Cancer

United States, Korea, Republic of, Israel, Japan, China, Australia
Japan Clinical Oncology Group
Ministry of Health, Labour and Welfare, Japan

Completed

Trial to Evaluate Radiotherapy With or Without CBDCA in Elderly Patients With Non-Small Cell Lung Cancer (JCOG0301)

Non-Small-Cell Lung Carcinoma

Japan
Hoffmann-La Roche

Active, not recruiting

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

Melanoma | Renal Cell Carcinoma | Adult Solid Tumor | Breast Cancer | Head and Neck Neoplasms | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Neuroendocrine Tumors | Lymphoma, Large-Cell, Anaplastic | Cholangiocarcinoma | Papillary Thyroid Cancer | Sarcomas | Salivary Gland Cancers and other conditions

United States, China, Korea, Republic of, Australia, Taiwan, France, Spain, United Kingdom, Hong Kong, Belgium, Italy, Germany, Japan, Singapore, Netherlands, Poland
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Well-differentiated Non-functional NET of Thoracic Origin | Well-differentiated Non-functional NET of Gastrointestinal Origin | Well-differentiated Non-functional NET of Pancreatic Origin | Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma

United States, Italy, Spain, Japan, Belgium, Netherlands, Germany, France, Canada, Austria, United Kingdom, Australia
Stanford University

Completed

Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)

Non-small Cell Lung Cancer (NSCLC)

United States, Japan, Canada
AstraZeneca

Completed

Iressa Case Control Study in Japan

Non-small Cell Lung Cancer

Japan
Japan Multinational Trial Organization

Completed

Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer

Lung Cancer

Japan
Sanofi

Active, not recruiting

Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA (CARMEN-LC06)

Non-squamous Non-small Cell Lung Cancer

Belgium, Italy, Spain, Japan, United States, France, Turkey
Amgen

Completed

A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) (FORTITUDE-201)

Squamous-Cell Non-Small-Cell Lung Cancer

France, Belgium, Spain, United States, Taiwan, Korea, Republic of, Japan, Poland
National Hospital Organization Kinki-chuo Chest...

Unknown

Quality of Life in Patients Who Are Receiving Either Vinorelbine, Gemcitabine, and Docetaxel or Paclitaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer

Lung Cancer

Japan
Pfizer

Terminated

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Australia, Japan
AstraZeneca

Active, not recruiting

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Advanced Non Small Cell Lung Cancer

Canada, Poland, Taiwan, United States, Korea, Republic of, Japan, Russian Federation, Ukraine
MedImmune LLC

Terminated

A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Canada, Japan, Poland, Germany, Hungary, France
Pfizer

Recruiting

Lorlatinib Continuation Study

NSCLC | Non-Small-Cell Lung Cancer

Spain, China, Taiwan, France, Singapore, Japan, United States
AstraZeneca

Active, not recruiting

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (ARTEMIDE-01)

Non-Small-Cell Lung Carcinoma

France, Spain, Thailand, Belgium, Korea, Republic of, Netherlands, United States, Brazil, Japan, China, Malaysia, Taiwan, Australia, Denmark
Novartis Pharmaceuticals

Terminated

This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N)

Non-small Cell Lung Cancer

Canada, Netherlands, Spain, France, Japan, Russian Federation, Germany, Belgium, Greece, Turkey, Taiwan, United States
Taiho Oncology, Inc.

Completed

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

Advanced or Metastatic Non-small Cell Lung Cancer

United States, France, Poland, Spain, Italy, Japan
Novartis Pharmaceuticals

Completed

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

Non-small Cell Lung Cancer

China, Taiwan, Belgium, Netherlands, Spain, Germany, Singapore, Italy, Japan, Australia, Israel, Korea, Republic of, Thailand, France
AstraZeneca

Completed

AZD9291 First Time In Patients Ascending Dose Study (AURA)

Advanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung Cancer

United States, France, Germany, Korea, Republic of, Taiwan, United Kingdom, Spain, Italy, Japan, Australia
AstraZeneca

Withdrawn

Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel

Cancer | Non Small Cell Lung Cancer | Epithelial Ovarian Cancer

Japan

Clinical Trials on NK/T Cell Lymphoma Nos in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations